Assess whether a CMO finding is a delay or a refuse-to-file risk (3ddd28)

Situation

After a site-change that invalidates stability claims, complete-response-letter deficiency list is what pharmacovigilance medical reviewer can touch in a safety team sitting on a new disproportionate signal. Pharma & Life Sciences will live with A CMO finding is a delay versus A refuse-to-file risk on this FDA Response and Labeling file.

Decision

Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using complete-response-letter deficiency list after a site-change that invalidates stability claims.

Hypotheses to test

• Authorize A CMO finding is a delay now; complete-response-letter deficiency list already has the discriminator after a site-change that invalidates stability claims.
• Keep A refuse-to-file risk in force until complete-response-letter deficiency list is completed after a site-change that invalidates stability claims for pharmacovigilance medical reviewer.
• Treat complete-response-letter deficiency list as A CMO finding is a delay because both readings appear after a site-change that invalidates stability claims.
• Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the page a CMO finding is turns on in complete-response-letter deficiency list.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• Check whether complete-response-letter deficiency list supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• For this Pharma & Life Sciences FDA Response and Labeling file, read complete-response-letter deficiency list against a site-change that invalidates stability claims and write the one fact that would move a CMO finding is for pharmacovigilance medical reviewer.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / FDA Response and Labeling packet (complete-response-letter deficiency list after a site-change that invalidates stability claims). The follow-on FDA Response and Labeling action is what pharmacovigilance medical reviewer does next: implement the option, assign an owner, and log the missing fact.